Effects of adding butyric acid to PN on gut-associated lymphoid tissue and mucosal immunoglobulin A levels.

Division of Traumatology, National Defense Medical College Research Institute, Tokorozawa, Japan.
Journal of Parenteral and Enteral Nutrition (Impact Factor: 3.14). 04/2011; 35(4):465-72. DOI: 10.1177/0148607110387610
Source: PubMed

ABSTRACT Parenteral nutrition (PN) causes intestinal mucosal atrophy, gut-associated lymphoid tissue (GALT) atrophy and dysfunction, leading to impaired mucosal immunity and increased susceptibility to infectious complications. Therefore, new PN formulations are needed to maintain mucosal immunity. Short-chain fatty acids have been demonstrated to exert beneficial effects on the intestinal mucosa. We examined the effects of adding butyric acid to PN on GALT lymphocyte numbers, phenotypes, mucosal immunoglobulin A (IgA) levels, and intestinal morphology in mice.
Male Institute of Cancer Research mice (n = 103) were randomized to receive either standard PN (S-PN), butyric acid-supplemented PN (Bu-PN), or ad libitum chow (control) groups. The mice were fed these respective diets for 5 days. In experiment 1, cells were isolated from Peyer's patches (PPs) to determine lymphocyte numbers and phenotypes (αβTCR(+), γδTCR(+), CD4(+), CD8(+), B220(+) cells). IgA levels in small intestinal washings were also measured. In experiment 2, IgA levels in respiratory tract (bronchoalveolar and nasal) washings were measured. In experiment 3, small intestinal morphology was evaluated.
Lymphocyte yields from PPs and small intestinal, bronchoalveolar, and nasal washing IgA levels were all significantly lower in the S-PN group than in the control group. Bu-PN moderately, but significantly, restored PP lymphocyte numbers, as well as intestinal and bronchoalveolar IgA levels, as compared with S-PN. Villous height and crypt depth in the small intestine were significantly decreased in the S-PN group vs the control group, however Bu-PN restored intestinal morphology.
A new PN formula containing butyric acid is feasible and would ameliorate PN-induced impairment of mucosal immunity.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim To examine whether an enteral immune-modulating diet (IMD) enriched with whey-hydrolyzed peptide, fermented milk, and isomaltulose enhances gut associated lymphoid tissue (GALT) mass and function as compared with a standard enteral diet (STD). Methods Male ICR mice were randomized into the IMD (n = 10) or STD (n = 10) group. After 7 days of each feeding protocol, whole small intestines were harvested. GALT lymphocytes from Peyer's patches (PPs), intraepithelial spaces (IE) and the lamina propria (LP) were isolated, counted and subjected to phenotypic determination by flowcytometry (αβTCR+, γδTCR+, CD4+, CD8+ and B cells). In another set of mice (IMD; n = 13, STD; n = 13), immunoglobulin A (IgA) levels of small intestinal, nasal and broncho-alveolar washings were measured with ELISA. Results Total lymphocyte numbers in PPs and LP and absolute numbers of B cells in PPs, γδTCR + cells in IE and αβTCR+, γδTCR+, CD4+, and CD8+ cells in LP were significantly higher in the IMD than in the STD group. IgA levels of small intestinal washings were significantly higher in the IMD than in the STD group with no differences in respiratory tract IgA levels. Conclusion The new IMD increases GALT mass and gut IgA levels as compared with STD.
    e-SPEN Journal. 12/2013; 8(6):e241–e245.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The gastrointestinal tract has a major role in digestion and absorption of nutrients while playing a leading role in defense of the body. It forms a shield against the invasion of various microorganisms or their products (e.g. antigens, toxins) and therefore it is important to establish its integrity and functionality. That depends on the route of administration and the composition of the artificial nutrition. This study concentrates on the influences of different kinds of artificial nutrition in the functionality of the intestinal mucosal barriers. It seems that full macromolecular solutions of enteral nutrition ensure an adequate mucous immune response, while a lack of nutritional stimulus in the lumen leads rapidly to a dysfunction of gastric-associated lymphatic tissue and mucosal immune system. This dysfunction renders the patients susceptible to infections in distant organs, hospital pneumonia, and multiorgan failure of non-infectious etiology. In patients with indication of total parenteral nutrition administration, addition of bombesin or glutamine preserves mucosal immune response and may limit the adverse effects. © 2013 S. Karger AG, Basel.
    Digestion 11/2013; 88(3):193-208. · 2.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Enteral nutrition is recommended as a standard nutritional therapy in clinical settings. The rationale behind enteral nutrition may be decreased infectious morbidities compared with parenteral nutrition. However, the mechanism may not be well understood. Animal studies have revealed that enteral nutrition, compared with parenteral nutrition, preserves the gut-associated lymphoid tissue mass and function with well controlled gut cytokine milieu and intracellular signaling pathway, leading to the maintenance of intestinal and extraintestinal acquired mucosal immunity. Moreover, enteral nutrition can enhance the gut innate immunity by increasing the antimicrobial peptides, such as secretory phospholipase A2. More importantly, a recent clinical study demonstrated preoperative parenteral nutrition without enteral nutrition to decrease the number of T cells, IgA-producing cells, and mature dendritic cells in human terminal ileum, which are consistent with the data obtained from animal studies. Investigation of the mechanism has given us some surrogates of enteral nutrition during parenteral nutrition, such as glutamine, butyric acid, cytokines, and other mediators. However, to date, no surrogates can restore parenteral-nutrition-induced impairment of host defense completely. Because enteral nutrition is a practical way to preserve gut immunity, clinicians should make any efforts to shorten the period of enteral nutrition absence and increase the dose according to the degree of tolerance.
    Current opinion in clinical nutrition and metabolic care. 03/2014; 17(2):164-70.


Available from